Weight-loss drugs are supposed to be forever. Until they run out.
Waibel went through two months’ worth of Wegovy before Waibel’s pharmacy ran out. All the CVS, Walgreens and Wegmans stores within a few hours’ drive from Waibel’s home in
As weight-loss drugs take off, doctor says these foods are just as powerful
According to health experts, if you eat the right foods, your body will trigger the natural release of GLP-1 – which is what injectable weight-loss drugs do.
Nearly $270,000 in fake weight loss drugs seized in Cincinnati
Hundreds of thousands of dollars worth of fake weight loss drugs were discovered during inspections and seized by Cincinnati U.S. Customs and Border Protection in conjunction with the FDA.
Weight-loss drugs have changed culture
F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.
BioAge valued at $758 million in debut as investors bet on weight-loss drug frenzy
By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
Weight-loss drug developer BioAge raises $198 million in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. The surging popularity of weight-loss drugs,
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...
New weight loss drugs spark eating disorder concerns in teens
BOSTON - There is concern over the newest weight loss drugs sparking eating disorders in teens. Newer GLP-1 weight loss drugs ...
Weight loss drugs like Ozempic and Wegovy are tremendously popular and effective. Patients should also be careful in using them
Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...
Medical News Today3h
Weight-loss surgery may preserve kidney health more effectively than GLP-1 drugs
People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...
Business Wire1d
More Than 90% of Likely Voters Are Concerned About Safety and Regulation of Compounded Weight Loss Drugs
Ninety percent say the FDA should use their existing authority to ensure these compounded weight loss drugs are safe. Compounded medicines serve an important role in the U.S. healthcare system ...
WTVD2d
NC put in spotlight during congressional hearing on weight loss drugs cost with company's CEO
Sen. Bernie Sanders mentioned that North Carolina ended coverage of Wegovy for state employees due to the cost.